REVVITY, INC.

During fiscal year 2023, we completed the sale of certain assets and the equity interests constituting our Applied, Food and Enterprise Services businesses (the “Business”) for approximately $2.27 billion in cash proceeds before transaction costs. During fiscal year 2023 and fiscal year 2024, we recognized a pre-tax gain (loss) on sale of $811.5 million and $(25.4) million, respectively. During fiscal year 2023 and fiscal year 2024, we recognized income (loss) from discontinued operations of $513.6 million and $(12.7) million, respectively. The Business was a component of our Discovery & Analytical Solutions segment, which is now referred to as the Life Sciences segment. The sale of the Business was reported as discontinued operations in our condensed consolidated financial statements.

During the three months ended June 29, 2025 and June 30, 2024, we recorded a gain (loss) on sale of $1.1 million and $(23.7) million, respectively, and a provision for income taxes of $0.2 million and $6.5 million, respectively, related to the sale of the Business. During the six months ended June 29, 2025 and June 30, 2024, we recorded a gain (loss) on sale of $0.3 million and $(25.5) million, respectively, and a provision for income taxes of $0.4 million and $5.5 million, respectively, related to the sale of the Business.